New York, New York 10025

  • Ischemic Heart Disease


The primary purpose of this study is to determine the optimal time for myocardial perfusion imaging with Technetium Tc99m Sestamibi following the administration of BMS068645. The safety of BMS068645 will also be studied.


Inclusion Criteria: - 18 years of age or older - Have known or suspected heart disease - Have undergone a clinically indicated SPECT MPI study with adenosine in the last 24 hours to 14 days. - Weigh between 88 and 250 lbs. Exclusion Criteria: - Allergic reaction to Technetium Tc99m Sestamibi or any of its components - History of asthma or lung disease - Ingestion of caffeinated substances within 12 hours prior to the study



Primary Contact:

Principal Investigator
E Gordon DePuey, MD
St. Luke's-Roosevelt Hospital Center

Backup Contact:


Location Contact:

New York, New York 10025
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.